scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (SCPH)

Q: What does CUSIP 810648105 represent in this 13F holders report?

CUSIP 810648105 is the security identifier for SCPH - scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held SCPH - scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share in Q4 2020?

46 institutional investors reported SCPH - scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share for Q4 2020. Use the holders table for investor-level position and value details.

CUSIP: 810648105

Q4 2020 13F Holders as of 31 Dec 2020

Security type / class: Equity / Common Stock, par value $0.0001 per share
Total 13F shares: 16,944,254
Total 13F value: $89,636,480
Share change: -787,184
SEC-reported price per share: $5.29
Number of holders: 46
Value change: -$6,272,494
Number of buys: 22
Number of sells: 23
Shares outstanding: 53,364,241

Security key

810648105

Report period

Q4 2020

Institutions

Top holders

SCPH full security history Ownership snapshot Full 13F holder table scPharmaceuticals Inc. SEC filings scPharmaceuticals Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of SCPH - scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

ORBIMED ADVISORS LLC

Disclosed value leader

ORBIMED ADVISORS LLC

Comparable rows

15/15

Latest evidence

30 Sep 2020

13F Lead comparable stake: 9% Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 9%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.

Comparable ownership Top 5

ORBIMED ADVISORS LLC 9%

5AM Venture Management, LLC 7.2%

RA CAPITAL MANAGEMENT, L.P. 6.6%

Ikarian Capital, LLC 2.8%

DRIEHAUS CAPITAL MANAGEMENT LLC 1.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
ORBIMED ADVISORS LLC	13F Company 13F	9%	$35,739,000 4,797,148 shares	—	30 Sep 2020
5AM Venture Management, LLC	13F Company 13F	7.2%	$28,544,000 3,831,474 shares	—	30 Sep 2020
RA CAPITAL MANAGEMENT, L.P.	13F Company 13F	6.6%	$26,217,000 3,518,998 shares	—	30 Sep 2020
Ikarian Capital, LLC	13F Company 13F	2.8%	$11,033,000 1,481,147 shares	—	30 Sep 2020
DRIEHAUS CAPITAL MANAGEMENT LLC	13F Company 13F	1.4%	$5,494,000 737,467 shares	—	30 Sep 2020
VANGUARD GROUP INC	13F Company 13F	1.1%	$4,393,000 589,676 shares	—	30 Sep 2020

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2020

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

16,944,254

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2020 vs Q3 2020 Across Filers

Q3 2020 holders

Q4 2020 holders

Holder diff

-2

Investor	Q3 2020 Shares	Q4 2020 Shares	Share Diff	Share Chg %	Q3 2020 value	Q4 2020 value	Value change	Value Chg %